Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Aug;13(4):295-300.
doi: 10.4196/kjpp.2009.13.4.295. Epub 2009 Aug 31.

The Inhibitory Effect of Quercetin-3-O-beta-D-Glucuronopyranoside on Gastritis and Reflux Esophagitis in Rats

Young Sil Min  1 , Se Eun Lee, Seung Tae Hong, Hyun Sik Kim, Byung-Chul Choi, Sang Soo Sim, Wan Kyun Whang, Uy Dong Sohn
Affiliations

The Inhibitory Effect of Quercetin-3-O-beta-D-Glucuronopyranoside on Gastritis and Reflux Esophagitis in Rats

Young Sil Min et al. Korean J Physiol Pharmacol. 2009 Aug.

Abstract

It was evaluated the inhibitory action of quercetin-3-O-beta-D-glucuronopyranoside (QGC) on reflux esophagitis and gastritis in rats. QGC was isolated from the herba of Rumex Aquaticus. Reflux esophagitis or gastritis was induced surgically or by administering indomethacin, respectively. Oral QGC decreased ulcer index, injury area, gastric volume, and acid output and increased gastric pH as compared with quercetin. Furthermore, QGC significantly decreased gastric lesion sizes induced by exposing the gastric mucosa to indomethacin. Malondialdehyde levels were found to increase significantly after inducing reflux esophagitis, and were reduced by QGC, but not by quercetin or omeprazole. These results show that QGC can inhibit reflux esophagitis and gastritis in rats.

Keywords: Gastritis; Lipid peroxidation; Quercetin-3-O-β-D-glucuronopyranoside; Reflux esophagitis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The effect of QGC on reflux esophagitis induced surgically in rats. Mean lesion area in the control group was 4 (0, no lesion; 1, ulcer area; 2, ulcer area <30 mm2; 3, ulcer area >30 mm2; 4, complete lesion (perforation of the esophageal mucosa). QGC treated animals showed significantly inhibition on reflux esophagitis. Data are means±SEMs of 6~8 animals. *Significantly different from the corresponding controls. *p<0.05, **p<0.01, and ***p<0.001 vs. the control.
Fig. 2
Fig. 2
The effect of QGC on gastric volume. QGC significantly and dose-dependently decreased gastric volume. Data are means±SEM. *p<0.05, **p<0.01, and ***p<0.001 vs. the control (n=6~8).
Fig. 3
Fig. 3
The effects of QGC on gastric pH. QGC administration changed the pH of reflux esophagitis in rats. QGC significantly increased when compared with the pH of quercetin. Data are means±SEM. *p<0.05, ***p<0.001 vs. the control (n=6~8).
Fig. 4
Fig. 4
The inhibitory effect of QGC on gastric acid output. QGC significantly increased when compared to the acidity of quercetin. Data are means±SEM. *Significantly different from the corresponding control. *p<0.05, **p<0.01, and ***p<0.001 vs. the control (n=6~8).
Fig. 5
Fig. 5
The inhibitory effects of QGC on lipid peroxidation. In the gastritis control group levels of lipid peroxidation were elevated as compared with the normal group. QGC administration significantly decreased the amount of MDA formation, suggesting that it inhibited gastritis induced lipid peroxidation. Column represent means±SEMs of 6~8 animals. *p<0.05 and **p<0.01 vs. control.
Fig. 6
Fig. 6
The inhibitory effect of QGC on indomethacin-induced gastritis. Mean lesion area in the control group was 4.0±0.7 cm2. QGC (0.001~0.01 mg/kg, p.o.) dose-dependently inhibited the formation of indomethacin-induced lesions. Data are means±SEM of 6~8 animals. *Significantly different from the corresponding control. *p<0.05 and ***p<0.001 vs control.
See this image and copyright information in PMC

References

    1. Alvarez A, Pomar F, Sevilla, Montero MJ. Gastric antisecretory and antiulcer activities of an ethanolic extract of Bidens pilosa L. var. radiata Schult. Bip. J Ethnopharmacol. 1999;67:333–340. - PubMed
    1. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt H. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992;51(Suppl 1):59–67. - PubMed
    1. Bell NJ, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut. 1992;33:118–124. - PMC - PubMed
    1. Biancani P, Sohn UD, Rich HG, Harnett KM, Behar J. Signal transduction pathways in esophageal and lower esophageal sphincter circular muscle. Am J Med. 1997;103:23S–28S. - PubMed
    1. Bradford MM. A rapid, sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254. - PubMed